Novo Nordisk lawsuit won’t delay Pfizer’s launch of Exubera

Share this article:
Novo Nordisk won’t be able to get a court injunction immediately to stop Pfizer’s planned September launch of its inhalable insulin Exubera. US Judge Leonard Sand in New York has scheduled a hearing for Dec. 4 to consider Novo Nordisk’s motion filed last week asking for a preliminary injunction to block Pfizer from selling Exubera. Earlier this month, Novo Nordisk sued Pfizer claiming the new product Exubera violates Novo Nordisk patents on inhalable insulin. “You can’t just snap your fingers and get a preliminary injunction,” David Tulchin, an attorney with Sullivan & Cromwell, the firm representing Novo Nordisk, told Web site Marketwatch.com. Tulchin said the hearing for the preliminary injunction was scheduled for December to give Pfizer time to respond to Novo Nordisk’s motion. A Pfizer spokesman told Marketwatch his company has not changed its plans to make initial supplies of Exubera available next month. Tulchin said that Pfizer runs the risk of having to halt sales of Exubera if Novo Nordisk is successful in getting an injunction. Pfizer and some market analysts predict Exubera to eventually exceed $1 billion in annual sales.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Sales

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.